NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route (Ascending) | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
10631-0004-31 | 10631-0004 | isotretinoin | Absorica LD | 20.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Nov. 20, 2019 | In Use | |
10631-0005-31 | 10631-0005 | isotretinoin | Absorica LD | 24.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Nov. 20, 2019 | In Use | |
10631-0006-31 | 10631-0006 | isotretinoin | Absorica LD | 28.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Nov. 20, 2019 | In Use | |
10631-0007-31 | 10631-0007 | isotretinoin | Absorica LD | 32.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Nov. 20, 2019 | In Use | |
60505-4630-03 | 60505-4630 | Cyclosporine | CycloSPORINE, Modfied | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Nov. 5, 2019 | Aug. 31, 2023 | In Use |
72205-0006-60 | 72205-0006 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | July 21, 2018 | In Use | |
60505-4631-03 | 60505-4631 | Cyclosporine | CycloSPORINE, Modfied | 50.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Nov. 5, 2019 | Aug. 31, 2023 | In Use |
70518-1966-00 | 70518-1966 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | March 19, 2019 | In Use | |
75987-0140-13 | 75987-0140 | Cysteamine bitartrate | PROCYSBI | 75.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | Feb. 14, 2020 | In Use | ||
75987-0140-14 | 75987-0140 | Cysteamine bitartrate | PROCYSBI | 75.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | Feb. 14, 2020 | In Use | ||
75987-0145-13 | 75987-0145 | Cysteamine bitartrate | PROCYSBI | 300.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | Feb. 14, 2020 | In Use | ||
75987-0145-14 | 75987-0145 | Cysteamine bitartrate | PROCYSBI | 300.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | Feb. 14, 2020 | In Use | ||
70518-2256-00 | 70518-2256 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug. 7, 2019 | In Use | |
63850-0004-01 | 63850-0004 | Ondansetron Tablets | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 25, 2007 | In Use | |
72237-0102-02 | 72237-0102 | selinexor | XPOVIO | 40.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | May 19, 2021 | In Use | |
72237-0102-06 | 72237-0102 | selinexor | XPOVIO | 40.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | May 19, 2021 | In Use | |
72237-0102-07 | 72237-0102 | selinexor | XPOVIO | 40.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | May 19, 2021 | In Use | |
71205-0537-06 | 71205-0537 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 21, 2021 | In Use | |
71205-0537-07 | 71205-0537 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 21, 2021 | In Use | |
71205-0537-10 | 71205-0537 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 21, 2021 | In Use | |
71205-0537-12 | 71205-0537 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 21, 2021 | In Use | |
71205-0537-20 | 71205-0537 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 21, 2021 | In Use | |
71205-0537-21 | 71205-0537 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 21, 2021 | In Use | |
71205-0537-30 | 71205-0537 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 21, 2021 | In Use | |
71205-0537-60 | 71205-0537 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 21, 2021 | In Use | |
71205-0537-90 | 71205-0537 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 21, 2021 | In Use | |
78206-0153-01 | 78206-0153 | FINASTERIDE | PROSCAR | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | June 1, 2021 | In Use | |
78206-0153-02 | 78206-0153 | FINASTERIDE | PROSCAR | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | June 1, 2021 | In Use | |
72237-0103-05 | 72237-0103 | selinexor | XPOVIO | 50.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | May 19, 2021 | In Use | |
00093-9018-65 | 00093-9018 | Cyclosporine | Cyclosporine | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | June 8, 2021 | In Use | |
00093-9019-65 | 00093-9019 | Cyclosporine | Cyclosporine | 50.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | June 8, 2021 | In Use | |
00093-9020-65 | 00093-9020 | Cyclosporine | Cyclosporine | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | June 8, 2021 | In Use | |
00245-0575-01 | 00245-0575 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | June 25, 2021 | In Use | |
00310-0610-28 | 00310-0610 | SELUMETINIB | KOSELUGO | 10.0 mg/1 | Chemotherapy | MEK Inhibitor | MEK 1/2 | Oral | June 11, 2021 | In Use | |
00310-0610-60 | 00310-0610 | SELUMETINIB | KOSELUGO | 10.0 mg/1 | Chemotherapy | MEK Inhibitor | MEK 1/2 | Oral | April 16, 2020 | In Use | |
00310-0625-28 | 00310-0625 | SELUMETINIB | KOSELUGO | 25.0 mg/1 | Chemotherapy | MEK Inhibitor | MEK 1/2 | Oral | June 11, 2021 | In Use | |
00310-0625-60 | 00310-0625 | SELUMETINIB | KOSELUGO | 25.0 mg/1 | Chemotherapy | MEK Inhibitor | MEK 1/2 | Oral | April 16, 2020 | In Use | |
42806-0133-21 | 42806-0133 | Leucovorin Calcium | Leucovorin Calcium | 10.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jan. 1, 2021 | In Use | |
42806-0133-24 | 42806-0133 | Leucovorin Calcium | Leucovorin Calcium | 10.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jan. 1, 2021 | In Use | |
60505-4764-06 | 60505-4764 | Abiraterone acetate | Abiraterone acetate | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | July 16, 2021 | In Use | |
60760-0715-12 | 60760-0715 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | July 6, 2021 | In Use | |
60760-0715-21 | 60760-0715 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 25, 2020 | In Use | |
62332-0565-30 | 62332-0565 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | July 9, 2021 | In Use | |
62332-0565-90 | 62332-0565 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | July 9, 2021 | In Use | |
62332-0566-30 | 62332-0566 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | July 9, 2021 | In Use | |
62332-0566-90 | 62332-0566 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | July 9, 2021 | In Use | |
62332-0567-30 | 62332-0567 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | July 9, 2021 | In Use | |
62332-0567-90 | 62332-0567 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | July 9, 2021 | In Use | |
68788-7961-01 | 68788-7961 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | July 16, 2021 | In Use | ||
68788-7961-03 | 68788-7961 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | July 16, 2021 | In Use | ||
68788-7961-06 | 68788-7961 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | July 16, 2021 | In Use | ||
68788-7961-09 | 68788-7961 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | July 16, 2021 | In Use | ||
71205-0908-00 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 16, 2021 | In Use | |
71205-0908-11 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 16, 2021 | In Use | |
71205-0908-30 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 16, 2021 | In Use | |
71205-0908-55 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 16, 2021 | In Use | |
71205-0908-60 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 16, 2021 | In Use | |
71205-0908-90 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 16, 2021 | In Use | |
70954-0056-10 | 70954-0056 | Prednisone | Prednisone | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | July 6, 2021 | In Use | |
70954-0056-20 | 70954-0056 | Prednisone | Prednisone | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | July 6, 2021 | In Use | |
72189-0246-07 | 72189-0246 | PREDNISONE | PREDNISONE | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | July 8, 2021 | In Use | |
72606-0573-01 | 72606-0573 | Abiraterone acetate | Abiraterone acetate | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | July 22, 2021 | In Use | |
72237-0104-01 | 72237-0104 | selinexor | XPOVIO | 60.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | May 19, 2021 | In Use | |
68788-9309-05 | 68788-9309 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | June 22, 2017 | In Use | |
68788-9309-06 | 68788-9309 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 26, 2015 | In Use | |
68788-9309-07 | 68788-9309 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 26, 2015 | In Use | |
68788-9309-08 | 68788-9309 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 26, 2015 | In Use | |
68788-9309-09 | 68788-9309 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 26, 2015 | In Use | |
61919-0235-10 | 61919-0235 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 7, 2019 | In Use | |
61919-0235-15 | 61919-0235 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 27, 2022 | In Use | |
61919-0235-21 | 61919-0235 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 1, 2014 | In Use | |
61919-0235-30 | 61919-0235 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 1, 2014 | In Use | |
61919-0235-40 | 61919-0235 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 29, 2019 | In Use | |
61919-0235-42 | 61919-0235 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 7, 2019 | In Use | |
60429-0834-01 | 60429-0834 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug. 16, 2016 | March 31, 2022 | In Use | |
60429-0834-05 | 60429-0834 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug. 16, 2016 | In Use | ||
42858-0868-06 | 42858-0868 | DRONABINOL | DRONABINOL | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 26, 2018 | In Use | |
42858-0867-06 | 42858-0867 | DRONABINOL | DRONABINOL | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 26, 2018 | In Use | |
42543-0139-90 | 42543-0139 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | June 29, 2018 | June 30, 2018 | No Longer Used |
68382-0641-06 | 68382-0641 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 16, 2018 | April 26, 2019 | No Longer Used |
68382-0641-16 | 68382-0641 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 16, 2018 | April 26, 2019 | No Longer Used |
53345-0037-01 | 53345-0037 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | April 25, 2018 | In Use | |
51013-0190-09 | 51013-0190 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 29, 2018 | In Use | |
51013-0190-30 | 51013-0190 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 29, 2018 | In Use | |
70771-1347-03 | 70771-1347 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 16, 2018 | In Use | |
70771-1347-09 | 70771-1347 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 16, 2018 | In Use | |
70771-1152-01 | 70771-1152 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 5, 2017 | In Use | |
70771-1152-00 | 70771-1152 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 5, 2017 | In Use | |
70771-1152-04 | 70771-1152 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 5, 2017 | In Use | |
70771-1152-03 | 70771-1152 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 5, 2017 | In Use | |
67046-0695-30 | 67046-0695 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | March 30, 2018 | Sept. 11, 2018 | No Longer Used |
68382-0074-01 | 68382-0074 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 5, 2017 | In Use | |
68382-0074-06 | 68382-0074 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 5, 2017 | In Use | |
68382-0074-10 | 68382-0074 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 5, 2017 | In Use | |
68382-0074-30 | 68382-0074 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 5, 2017 | Dec. 3, 2019 | In Use |
68382-0074-77 | 68382-0074 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 5, 2017 | In Use | |
70518-1198-00 | 70518-1198 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 15, 2018 | May 19, 2020 | No Longer Used |
70518-0892-00 | 70518-0892 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 12, 2017 | Jan. 6, 2020 | No Longer Used |
55700-0627-10 | 55700-0627 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 18, 2018 | In Use | |
55700-0627-12 | 55700-0627 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 18, 2018 | In Use |
Found 10,000 results in 8 milliseconds — Export these results